PROVECTUS PHARMACEUTICALS
Developing advanced therapies to target and destroy the deadliest cancers – melanoma, liver, and breast – while eliminating side effects
Developing advanced therapies to target and destroy the deadliest cancers – melanoma, liver, and breast – while eliminating side effects
Provectus Pharmaceuticals is a biotechnology and pharmaceutical company that is dedicated to developing advanced therapies to target and destroy the deadliest cancers, including melanoma, liver, and breast cancers, while also placing a significant emphasis on reducing side effects. Established in 1978 as "SPM Group, Inc.," the company underwent a transition in 1992 to refocus its efforts on pursuing acquisitions. With a last investment of $3.37M in post-IPO equity that took place on April 17, 2014, Provectus Pharmaceuticals continues to attract attention and support within the industry. The company's innovative approach and strategic positioning within the biotechnology and pharmaceutical industries make it a compelling prospect for investors seeking to contribute to the advancement of cancer treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $3.37M | - | 17 Apr 2014 | |
| Post-IPO Equity | $4.51M | - | 07 Aug 2009 | |
| Post-IPO Equity | $2.71M | - | 30 Jun 2009 |
No recent news or press coverage available for PROVECTUS PHARMACEUTICALS.
We care about your data, and we'd love to use cookies make your experience better.
